Nova Anchora

Raised $23M, announced 5 November 2026.

Total raised: $23M

Country United StatesSector Health

Round

$23MRound, 5 November 2026

Nova Anchora raised $23 million in equity financing to manufacture NvA-021, complete IND-enabling work, and advance an initial clinical proof-of-concept study.

Update 5 November 2026 The financing includes an initial tranche and additional capital tied to specified development milestones. globenewswire.com

Amount: $23M
Announced: 5 November 2026
Lead: Viking Global Investors
Other investors: DEBRA Research gGmbH, EB Research Partnership (EBRP), EB Medical Research Foundation (EBMRF), Cure EB
Use of funds: Complete IND-enabling studies, manufacture clinical supply, submit IND application to FDA, conduct clinical proof-of-concept study.
Checked: Announced by the company
Source: Nova Anchora Announces $23 Million Financing to Advance Topical Collagen VII Therapy for Dystrophic Epidermoly globenewswire.com

Company

Develops topical protein therapies for dystrophic epidermolysis bullosa

Based in: BOSTON, United States
Sector: Health
Website: novaanchora.com ↗

Founders

Jason Bhardwajco-founder and Chief Executive OfficerLinkedIn ↗
Peter Marinkovichco-founder and Chair of the Scientific Advisory Board

Questions

How much has Nova Anchora raised?

Nova Anchora raised $23M, announced on 5 November 2026.

Who invested in Nova Anchora?

Viking Global Investors led. Investors include Viking Global Investors, DEBRA Research gGmbH, EB Research Partnership (EBRP), EB Medical Research Foundation (EBMRF) and Cure EB.